MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
0.8851
-0.0149
-1.66%
After Hours: 0.8850 -0.0001 -0.01% 19:50 03/27 EDT
OPEN
0.8800
PREV CLOSE
0.9000
HIGH
0.9272
LOW
0.8400
VOLUME
1.24M
TURNOVER
0
52 WEEK HIGH
1.120
52 WEEK LOW
0.4126
MARKET CAP
162.52M
P/E (TTM)
-0.6092
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at NKTR last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at NKTR last week (0311-0315)?
Weekly Report · 03/18 09:24
Weekly Report: what happened at NKTR last week (0304-0308)?
Weekly Report · 03/11 09:24
Nektar Therapeutics Is Worried About This – Should You Be Worried Too?
TipRanks · 03/07 06:00
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
NASDAQ · 03/06 17:33
Nektar Therapeutics Is Maintained at Hold by Jefferies
Dow Jones · 03/06 14:54
Nektar Therapeutics Price Target Raised to $1.00/Share From $0.50 by Jefferies
Dow Jones · 03/06 14:54
Jefferies Maintains Hold on Nektar Therapeutics, Raises Price Target to $1
Benzinga · 03/06 14:44
More
About NKTR
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its pipeline NKTR-255 is an investigational biologic that is designed to target the interleukin-15 (IL-15) pathway in order to activate the body’s innate and adaptive immunity. Its Rezpegaldesleukin (REZPEG) pipeline is an investigational, potential first-in-class T regulatory cell stimulator that addresses this underlying immune system imbalance in people with many autoimmune and inflammatory conditions. REZPEG is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.